Principia Biopharma to Present at the 2019 Bank of America Merrill Lynch Health Care Conference
May 09, 2019 16:01 ET
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to...
Principia Biopharma Reports First Quarter Financial Results
May 07, 2019 16:01 ET
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to...
Principia Biopharma Appoints Shao-Lee Lin, M.D., Ph.D. to Board of Directors
April 18, 2019 16:01 ET
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Calif., April 18, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to...
Principia Biopharma Reports Fourth Quarter and Full Year 2018 Financial Results
March 19, 2019 16:01 ET
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Calif., March 19, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to...
Principia Biopharma Reacquires Rights to Oral Immunoproteasome Program
March 11, 2019 08:00 ET
|
Principia Biopharma Inc.
-- Principia and AbbVie mutually agree to end collaboration ---- Preclinical stage program focused on development of oral immunoproteasome inhibitors to treat inflammation and autoimmune disorders -- ...
Principia Biopharma Announces Positive Data from Phase 2 Pemphigus Vulgaris Trial at 2019 American Academy of Dermatology Annual Meeting in Late-Breaking Presentation
March 02, 2019 14:20 ET
|
Principia Biopharma Inc.
-- Reached primary endpoint of Control of Disease Activity at four weeks in 54 percent of patients on low dose corticosteroids ---- Median Anti-DSG antibodies reduced by up to 65 percent with 12 weeks...
Principia Biopharma Presents Phase 1 Clinical Data from CNS Penetrating BTK Inhibitor Candidate PRN2246/SAR442168 at ACTRIMS 2019
March 01, 2019 08:00 ET
|
Principia Biopharma Inc.
-- Orally administered PRN2246 achieved full BTK occupancy in peripheral blood ---- PRN2246 exhibited blood-brain barrier permeability and CNS exposure ---- Sanofi to lead Phase 2 development for...
Principia Biopharma Announces the Acceptance of Data from Phase 2 Pemphigus Vulgaris Trial as a Late-Breaking Presentation at 2019 American Academy of Dermatology Meeting
February 22, 2019 08:00 ET
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to...
Principia Biopharma to Present at 8th Annual SVB Leerink Global Healthcare Conference
February 20, 2019 08:00 ET
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to...
Principia Biopharma Appoints John W. Smither to Board of Directors
February 19, 2019 16:10 ET
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to...